Avalo Therapeutics, INC Schedule 13G passive stakes

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 1,862,250 shares, representing 3.54% of Avalo Therapeutics, Inc.'s common stock as of June 30, 2026.

Caligan Partners LP and David Johnson have reported beneficial ownership of 5.9% of Avalo Therapeutics, Inc. common stock as of June 30, 2026.

RA Capital Management, along with affiliated entities and individuals, has reported beneficial ownership of 3,483,099 shares, representing 6.3% of Avalo Therapeutics, Inc.'s common stock.

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of 4.44% of Avalo Therapeutics, Inc. common stock.

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,610,000 shares, representing 6.87% of Avalo Therapeutics, Inc. common stock.

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting beneficial ownership of 10.8% of Avalo Therapeutics Inc.'s common stock as of July 31, 2026.

State Street Corporation has disclosed beneficial ownership of 5.5% of Avalo Therapeutics Inc.'s common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 9.7% of Avalo Therapeutics' common stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has filed a Schedule 13G, reporting beneficial ownership of Avalo Therapeutics, Inc. common stock.

Commodore Capital LP and its affiliates have reported beneficial ownership of 9.9% of Avalo Therapeutics, Inc. common stock, totaling 5,721,109 shares.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting a 6.1% beneficial ownership stake in Avalo Therapeutics Inc.

Deep Track Capital, LP and affiliates have reported a 5.81% beneficial ownership stake in Avalo Therapeutics, Inc. common stock.

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen have jointly filed a Schedule 13G, reporting beneficial ownership of 5.2% of Avalo Therapeutics' common stock.

Logos Global Management LP has filed a Schedule 13G reporting beneficial ownership of 1,675,000 shares of Avalo Therapeutics, Inc.

Caligan Partners LP and David Johnson have disclosed a beneficial ownership of 7.2% in Avalo Therapeutics, Inc., holding 1,635,023 shares.

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of over 5.75% of Avalo Therapeutics' common stock.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,340,840 shares, representing 5.5% of Avalo Therapeutics, Inc.'s common stock as of March 31, 2026.

TCG Crossover Fund II, L.P. and associated entities have reported a 7.9% beneficial ownership stake in Avalo Therapeutics, Inc. following a recent underwritten offering.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 12.6% in Avalo Therapeutics Inc. as of March 31, 2026.

Logos Global Management LP and its affiliates have reported a 5.6% beneficial ownership stake in Avalo Therapeutics, Inc., comprising common stock and options.

FMR LLC and Abigail P. Johnson have reported a significant 11.5% beneficial ownership stake in Avalo Therapeutics Inc. common stock.

Millennium Management and affiliates report a 5.0% passive beneficial ownership in Avalo Therapeutics, Inc. common stock.

Balyasny Asset Management and its affiliates reported a passive beneficial ownership of 2.42% in Avalo Therapeutics Inc., totaling 439,312 shares.

Millennium Management LLC and affiliates disclosed a 4.9% beneficial ownership in Avalo Therapeutics, Inc., indicating a reduction below the 5% reporting threshold.

SilverArc Capital Management and Devesh Gandhi have disclosed a passive 2.83% beneficial ownership stake in Avalo Therapeutics, Inc. Class A Common Stock.

Millennium Management LLC and affiliates reported a 4.9% passive stake in Avalo Therapeutics, Inc., having ceased to be beneficial owners of over 5% by the filing date.

The Vanguard Group has filed an amended Schedule 13G, reporting its beneficial ownership in Avalo Therapeutics Inc. has fallen to 4.43%.

Affinity Asset Advisors and Michael Cho have disclosed a 5.7% beneficial ownership stake in Avalo Therapeutics, Inc. through a Schedule 13G filing.

Ikarian Capital and Neil Shahrestani have filed an amendment to their Schedule 13G, disclosing a reduced beneficial ownership of 3.8% in Avalo Therapeutics, Inc.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.39% beneficial ownership stake in Avalo Therapeutics, Inc. as of September 30, 2025.